
## Michael Willis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5537673/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The public economic burden of subâ€optimal typeâ€2 diabetes control on tax payors in Sweden: Looking beyond health costs. Diabetes, Obesity and Metabolism, 2022, , .	2.2	2
2	Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Applied Health Economics and Health Policy, 2022, , 1.	1.0	1
3	Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with TypeÂ2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. Diabetes Therapy, 2021, 12, 313-328.	1.2	21
4	Macrovascular Risk Equations Based on the CANVAS Program. Pharmacoeconomics, 2021, 39, 447-461.	1.7	4
5	Swedish guidelines for deviceâ€aided therapies in Parkinson's disease —Economic evaluation and implementation. Acta Neurologica Scandinavica, 2021, 144, 170-178.	1.0	7
6	Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium. Acta Clinica Belgica, 2021, , 1-10.	0.5	1
7	Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data. Diabetes Therapy, 2020, 11, 2657-2676.	1.2	8
8	Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. Pharmacoeconomics, 2020, 38, 953-969.	1.7	16
9	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 2019, 37, 1305-1312.	1.7	28
10	Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. Diabetes Therapy, 2019, 10, 1753-1769.	1.2	11
11	Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes Research and Clinical Practice, 2019, 148, 222-233.	1.1	2
12	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues, 2019, 18, 65-73.	0.5	3
13	Cost-Effectiveness Analysis of Canagliflozin 300Âmg Versus Dapagliflozin 10Âmg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Therapy, 2018, 9, 565-581.	1.2	13
14	Multivariate Prediction Equations for HbA 1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling. Value in Health, 2017, 20, 357-371.	0.1	23
15	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Pharmacoeconomics, 2017, 35, 375-396.	1.7	24
16	Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. Journal of Population Therapeutics and Clinical Pharmacology, 2016, 23, e151-68.	1.4	8
17	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues, 2015, 8, 8-19.	0.5	17
18	Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations, PLoS ONE, 2014, 9, e110235.	1.1	34

MICHAEL WILLIS

#	Article	IF	CITATIONS
19	Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). Journal of Medical Economics, 2013, 16, 1007-1021.	1.0	27
20	Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. Schizophrenia Research and Treatment, 2012, 2012, 1-9.	0.7	14
21	The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. European Journal of Health Economics, 2010, 11, 585-594.	1.4	32
22	Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements. Applied Health Economics and Health Policy, 2010, 8, 377-386.	1.0	42
23	A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden. Clinical Drug Investigation, 2001, 21, 115-127.	1.1	11
24	The Emergence of Crack Cocaine and the Rise in Urban Crime Rates. Review of Economics and Statistics, 2000, 82, 519-529.	2.3	142